论文部分内容阅读
目的探讨应用不同剂量米非司酮治疗围绝经期功能失调性子宫出血的临床疗效与安全性。方法选取2013年3月至2014年2月治疗的围绝经期功能失调性子宫出血患者100例作为研究对象,随机分为A组(50例)和B组(50例)。给予米非司酮进行治疗,A组12.5 mg/d,B组6.5 mg/d,均为1次/d,疗程均为3个月。观察两组患者治疗前后子宫内膜厚度、血清雌二醇(E2)、促黄体激素(LH)及孕酮(P)水平的变化。结果 A组疗效显著优于B组,复发率明显低于B组(P均<0.05);两组不良反应发生率比较无统计学差异(P>0.05)。两组治疗后子宫内膜厚度均明显减小,差异有统计学意义(P<0.05),但组间比较差异无统计学意义(P>0.05);两组患者治疗后E2、LH、P水平比较差异有统计学意义(P<0.05)。结论应用12.5 mg/d剂量米非司酮治疗围绝经期功能失调性子宫出血临床疗效好,治愈率高,复发率和不良反应发生率低。
Objective To investigate the clinical efficacy and safety of different doses of mifepristone in treating peri-menopausal dysfunctional uterine bleeding. Methods 100 patients with peri-menopausal dysfunctional uterine bleeding who were treated from March 2013 to February 2014 were randomly divided into group A (50 cases) and group B (50 cases). Patients were treated with mifepristone, 12.5 mg / d in group A and 6.5 mg / d in group B, all in 1 / d, all for 3 months. The changes of endometrial thickness, serum estradiol (E2), luteinizing hormone (LH) and progesterone (P) in two groups before and after treatment were observed. Results The efficacy of group A was significantly better than that of group B, and the recurrence rate was significantly lower than that of group B (all P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). The thickness of endometrium in both groups were significantly decreased after treatment, the difference was statistically significant (P <0.05), but there was no significant difference between the two groups (P> 0.05); E2, LH and P levels after treatment The difference was statistically significant (P <0.05). Conclusion The application of 12.5 mg / d dose of mifepristone in the treatment of climacteric dysfunctional uterine bleeding has good clinical curative effect, high cure rate, recurrence rate and low incidence of adverse reactions.